U.S. Markets close in 35 mins
  • S&P 500

    4,406.83
    +52.64 (+1.21%)
     
  • Dow 30

    34,354.67
    +434.83 (+1.28%)
     
  • Nasdaq

    14,928.28
    +181.88 (+1.23%)
     
  • Russell 2000

    2,224.07
    +37.89 (+1.73%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,772.00
    -6.20 (-0.35%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1710
    -0.0021 (-0.1756%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    21.71
    -2.65 (-10.88%)
     
  • GBP/USD

    1.3644
    -0.0020 (-0.1446%)
     
  • USD/JPY

    109.7600
    +0.5400 (+0.4944%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,090.72
    +50.24 (+4.83%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Reminder: MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MARIETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 4:30 PM EST. Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.

About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@mimedx.com